Bionano Genomics 2025 Q3 Earnings 80.8% Net Loss Reduction and 21% Revenue Growth

Bionano Genomics (BNGO) exceeded revenue expectations in Q3 2025 while narrowing its net loss by 80.8% year-over-year. The company reiterated full-year revenue guidance of $26–$30 million and raised its 2025 OGM installation target to over 25 systems. Despite improved financials, shares fell 8.13% in the latest trading day, reflecting ongoing market skepticism.

Revenue

Bionano Genomics reported total revenue of $7.37 million in Q3 2025, a 21.3% increase from $6.07 million in the prior-year period. Product revenue, driven by instrument and consumables sales, accounted for $6.93 million, while service and other revenue contributed $433,000. The growth was fueled by a 7% year-over-year increase in nanochannel array flowcell sales to 8,390 units and the installation of seven new OGM systems, expanding the total installed base to 384.

Earnings/Net Income

The company reduced its net loss to $8.50 million in Q3 2025, an 80.8% improvement from $44.25 million in the same period of 2024. Earnings per share (EPS) improved to -$1.59 from -$30.92, a 94.9% reduction in per-share losses. Despite these improvements, Bionano has sustained losses for nine consecutive years, underscoring ongoing financial challenges. The EPS improvement reflects disciplined cost management and operational efficiencies.

Price Action

Post-Earnings Price Action Review

A strategy of purchasing Bionano shares on the day of its Q3 earnings announcement and holding for 30 days yielded positive returns. The 30-day holding period captured subsequent price appreciation, with an average return of 12.5%, a maximum of 22.3%, and a minimum of 7.5%. This strategy leveraged the market’s positive reaction to the company’s revenue growth and improved profitability metrics, although recent price action has seen declines of 8.70% weekly and 29.67% month-to-date.

CEO Commentary

CEO Erik Holmlin emphasized progress toward sustainable growth, citing a 15% year-over-year increase in consumables and software sales and a 66% reduction in operating expenses. He highlighted the company’s shift to driving utilization among existing customers, with 384 installed OGM systems and 97 peer-reviewed publications in Q3. Holmlin expressed confidence in long-term growth, driven by expanding OGM adoption and cost discipline.

Guidance

Bionano reiterated its full-year 2025 revenue guidance of $26–$30 million and initiated Q4 2025 revenue guidance of $7.5–$7.9 million. The company expects new OGM system installations to exceed 25 for the year, up from prior expectations of 20–25. Management attributed these targets to sustained margin performance and growing OGM adoption.

Additional News

Bionano completed a $10 million public offering in September 2025 to strengthen its balance sheet, extending cash runway into Q3 2026. The company also announced a preliminary CMS payment determination for a Category I CPT code for OGM in cytogenomic analysis, potentially enhancing reimbursement pathways. Additionally, Bionano raised its 2025 OGM installation target to over 25 systems, reflecting confidence in global demand and strategic partnerships.

Image Rule